Figure 6. JQ1 is a more potent inhibitor in MYC‐high PDX in vivo .

Four PDX with MYC‐high (CRCM16, CRCM04, CRCM114, and CRCM116) and four with MYC‐low (CRCM05, CRCM10, CRCM109, and CRCM112) phenotypes were treated with 50 mg/kg/day of JQ1 or with vehicle for 28 days by i.p. injections (n = 3 per group). ***P < 0.001, **P < 0.01 and *P < 0.05 in two‐way ANOVA with Bonferroni post‐test (mean ± SEM).Source data are available online for this figure.